CARY, N.C., Aug. 8, 2025 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that it has rescheduled its release of second quarter 2025 financial results and subsequent conference call. The Company…
